scientifica sessions.

Episode Description

North Carolina is often described through the lens of Research Triangle Park—but the real story is bigger than RTP.

In this first episode of Season 2 of scientifica sessions, we come home to unpack how North Carolina became one of the most complete life sciences ecosystems in the country: a hub built not on one asset, but on the full continuum from academic discovery to clinical development, CRO execution, biomanufacturing, and global commercialization.

Joined by Christian Brown and Mike Carnes of the North Carolina Biotechnology Center, this conversation explores how a state once known for agriculture, tobacco, and textiles intentionally transformed itself into a globally recognized life sciences engine. From the founding of RTP in the late 1950s to the creation of NC Biotech in 1984, North Carolina’s growth has been shaped by long-term state vision, academic strength, federal research anchors, and a convening infrastructure designed to help companies start, scale, and stay.

We explore how North Carolina is:

• Building across the entire biopharma value chain—from university research and biotech R&D to clinical trials, manufacturing, and sales.
• Leveraging NC Biotech as a statewide convener, investor, and ecosystem catalyst.
• Supporting early-stage companies through non-dilutive capital, loan funding, SBIR support, and investor syndication.
• Growing one of the strongest biomanufacturing workforces in the country through community colleges, BioWork, and university partnerships.
• Turning RTP 3.0 into a denser, more connected live-work-play innovation environment.
• Expanding life sciences beyond the Triangle into Holly Springs, Sanford, Wilson, Greenville, Winston-Salem, Charlotte, and other statewide clusters.

The conversation also dives into one of the most urgent issues facing American innovation: the uncertainty surrounding SBIR funding and foreign-risk reviews. Mike Carnes explains how opaque funding denials could slow early-stage company formation—not just in North Carolina, but across every U.S. innovation hub. Pasted text

What We Covered:

• Why North Carolina’s strength comes from diversification across the full life sciences value chain.
• How RTP grew from an anti–brain drain strategy into a self-sustaining innovation engine.
• Why NC Biotech’s early-stage funding model has helped companies raise billions in follow-on capital.
• How cost of doing business gives North Carolina a major advantage over Boston, San Diego, and the Bay Area.
• Why workforce—not just real estate or capital—is North Carolina’s clearest competitive advantage.
• How community colleges, universities, veterans programs, and mentorship create multiple pathways into the industry.

Takeaway: North Carolina didn’t become a life sciences hub by accident. It built the infrastructure, talent, capital pathways, and statewide connectivity to move science from idea to patient impact—and it is still building.

Connect with the guests 🔗 Christian Brown and Mike Carnes, North Carolina Biotechnology Center

📩 Connect with the show: [email protected]

Produced by Thread and Tensor

Episode Description:

Atlanta is often overlooked in the life sciences conversation—but what if that's exactly the point?

In this episode of scientifica sessions, we go inside the Atlanta ecosystem to unpack how a city built on public health leadership, world-class institutions, and deep clinical infrastructure is quietly assembling one of the most strategically compelling life sciences hubs in the United States.

Atlanta isn't trying to be Boston or San Diego. It's building something distinctly its own: a scale-up hub rooted in the interplay of the CDC, Emory University, Georgia Tech, a massive and diverse patient population, the world's busiest airport, and a collaboration culture that most markets can't manufacture.

We explore how Atlanta is:

• Defining its identity as a scale-up hub through Georgia's first-ever life sciences roadmap
• Attracting global companies like UCB to site U.S. manufacturing in the Southeast
• Building bio-literacy through K-12 programs that have reached over 270,000 students statewide
• Developing clinical infrastructure—including Children's Healthcare of Atlanta, home to more pediatric clinical trial beds than any U.S. children's hospital system
• Navigating the capital gap through government funding, foundations, and a maturing local venture ecosystem

The conversation also confronts the valley of death head-on—what it actually looks like when a company survives it through disciplined decision-making, capital efficiency, and the courage to move slowly when everything says move fast.

What We Covered:

• Why assets alone don't create a hub—and what the interplay looks like in Atlanta
• How Atlanta's distributed micro-hub structure creates both opportunity and challenge
• The real estate decisions that kill companies—and the discipline required to avoid them
• Why Atlanta's quality of life and cost structure are becoming a structural competitive advantage
• How Georgia's first life sciences roadmap is shaping the ecosystem's next decade

Takeaway: Atlanta didn't stumble into this moment. It built toward it for twenty years. The decade of intentionality starts now.

Connect with the guests 🔗 LinkedIn: Maria Thacker Goethe; Steven Damon; Justin Burns, Ph.D.; Andy Roberts

📩 Connect with the show: [email protected]

Produced by Thread and Tensor.

Episode Description:

Massachusetts is often viewed as the epicenter of biotech—but what actually makes this ecosystem work?

In this episode of scientifica sessions, we go inside the Commonwealth to unpack the deliberate strategy behind one of the most successful life sciences hubs in the world. Joined by leaders from the Massachusetts Life Sciences Center (MLSC) and founders building within the ecosystem, this conversation moves beyond Kendall Square to reveal a statewide model designed for scale, inclusion, and long-term impact.

At the center of it all is MLSC—a quasi-public engine deploying capital, building infrastructure, and shaping policy to ensure innovation doesn’t just start in Massachusetts, but stays and grows there.

We explore how Massachusetts has:

• Built a true public-private partnership across government, academia, and industry
• Used non-dilutive funding to de-risk early innovation and unlock venture capital
• Created intentional pathways for underrepresented founders through programs like Mass Next Gen
• Expanded beyond Boston to develop thriving clusters across the entire Commonwealth
• Leveraged density—not just of capital, but of experience, mentorship, and talent—to accelerate company growth

The conversation also dives into one of the most critical challenges in biotech—the “valley of death”—and how Massachusetts is actively building systems to help companies transition from early discovery to viable, revenue-generating businesses.

What emerges is a blueprint: an ecosystem that listens, evolves, and invests with purpose—across talent, infrastructure, capital, and community.

If you’re building, investing, or thinking about how to scale innovation in life sciences, this episode offers a rare look at what it takes to get it right.

What We Covered:

• The four pillars of a successful life sciences hub.
• Why non-dilutive funding is more than capital—it’s protection and development.
• How MLSC designs programs based on real ecosystem gaps.
• The role of density in mentorship, talent, and commercialization.
• Why the future of biotech ecosystems is statewide—not city-bound.

Takeaway:
Massachusetts didn’t become a global leader by chance—it built an intentional system to make innovation inevitable.

Connect with the guests
🔗 LinkedIn: Tiffany Walther, PhD; Samantha Johnson; Minmin (Mimi) Yen, PhD, MPH; Asmi Chakraborty, PhD; Ryan Mudawar

📩 Connect with the show: [email protected]

Produced by Thread and Tensor.

Episode Description

What if the next great American life sciences hub isn’t on the coasts—but in the heartland?

In this episode of scientifica sessions, we look beyond the usual biotech strongholds to explore Oklahoma’s emergence as a new life sciences contender. While Boston and San Francisco dominate the narrative, Oklahoma is quietly building a different model—one that blends energy-sector expertise, agricultural biotechnology, and targeted infrastructure investment to create a distinct innovation advantage.

Host Tabari Baker is joined by Oklahoma life sciences leaders:

• Carol Curtis, PhD
• Nicholete Davis
• Kelley Dowd, PhD
• Madison Jackson
• Patrick Lucy

Together, they unpack what it really takes to build a life sciences ecosystem from the ground up. This isn’t a generic “emerging hub” story—it’s a candid look at convergent innovation, where energy capital fuels therapeutic development, and regional strengths shape a new path forward.

In this episode, you’ll learn:

• Why Oklahoma’s “late start” may actually be a competitive advantage.
• How energy-industry capital and operational discipline are being repurposed for biotech.
• The infrastructure gaps that could accelerate—or constrain—ecosystem growth.
• What funding models are emerging before traditional venture capital arrives.
• How Oklahoma is addressing talent development without an established biotech workforce.
• The unique role of Native American healthcare systems in advancing innovation.

Key segments include:

• The Anatomy of a Hub: Foundational assets and authentic differentiators.
• Capital and Commercialization: Creative funding approaches and early success stories.
• Infrastructure and Place: Lab space, cost structure, and quality-of-life advantages.
• Talent Flywheels: Workforce pipelines and entrepreneurial culture building.

Whether you’re an entrepreneur deciding where to launch, an investor searching for untapped opportunity, or a life sciences leader tracking how innovation geography is shifting, this episode offers actionable insight into one of biotechnology’s most compelling frontier markets.

Connect with the guests
🔗 LinkedIn: Kelley Dowd, Nicholete Davis, Patrick Lucy, Carol Curtis, Madison Jackson

📩 Connect with the show: [email protected]

Produced by Thread and Tensor.

In this episode of scientifica sessions, host Tabari Baker (Founder & CEO, kronos scientifica) sits down with Dan Goddard, Business Development Lead at CFGO, to explore one of the most critical—and misunderstood—journeys in life sciences: moving a company from concept to capital.

Early-stage biotech lives at the intersection of breakthrough science, disciplined execution, and financial reality. When those elements align, companies build durable foundations that survive pivots, funding cycles, and market downturns. When they don’t, even exceptional science can stall. This conversation breaks down why that gap exists—and how founders can close it.

Dan brings decades of experience across early-stage biotech, venture-backed scaling companies, finance, planning, and investor readiness. Together, Dan and Tabari unpack what investors are actually looking for, why planning matters even when it’s guaranteed to change, and how discipline—not hype—drives long-term success.

In this episode, you’ll hear insights on:

• Why great science is necessary—but not sufficient—for fundraising.
• How to plan effectively when you know the plan will be wrong.
• Common budgeting mistakes founders make (and why being “under budget” can be a red flag).
• The importance of milestones, burn rate, and timing in a constrained funding environment.
• Why fractional expertise (finance, legal, regulatory) is essential for early-stage companies.
• Platform vs. asset strategies—and how AI is reshaping both.
• Lessons from prior biotech downturns and why contractions often produce the strongest companies.
• How founders should rethink fundraising as a partnership, not a transaction.

The conversation also dives into the human side of company building: decision fatigue, leadership vulnerability, early hiring challenges, and knowing when to ask for help. Dan shares hard-won lessons from working with dozens of companies—and why honest dialogue with investors often unlocks more value than a perfect pitch deck.

The episode closes with a powerful takeaway for founders navigating investor conversations:

If you want advice, ask for money. If you want money, ask for advice.

If you’re building, advising, or investing in early-stage biotech—and trying to understand what it really takes to turn innovation into impact—this episode is your playbook.

If You Liked This Episode…
Share it with your team and subscribe to scientifica sessions for unfiltered conversations with the leaders shaping biotech, pharma, and medtech.

Connect with Dan Goddard
🔗 LinkedIn: Dan Goddard

📩 Connect with the show: [email protected]

In this episode of scientifica sessions, host Tabari Baker (Founder & CEO, kronos scientifica) tackles one of the most persistent—and consequential—tensions in life sciences: the complicated relationship between Medical Affairs and Commercial. Too often it’s a “love–hate” dynamic fueled by shared stakeholders, unclear roles, conflicting metrics, and leadership misalignment. When it works, the field moves in lockstep. When it doesn’t, everyone feels it—especially HCPs.

Tabari is joined by two guests who live this challenge from different angles:

• Patrina Pellett, Co-CEO of MSL Mastery, who trains Medical Affairs teams on field excellence, communication, and cross-functional collaboration.

• Chase Wasson, a commercial executive with ~17 years across pharma, diagnostics, and medtech, who has seen collaboration drive real wins—and watched it break down when strategy and process aren’t aligned.

Together, they unpack the real root causes behind friction: “owning” the HCP relationship (and the turf wars it creates), the lack of role clarity during onboarding, and how leadership mindset trickles down into day-to-day behavior.

Chase argues that when strategy is aligned from the top, process follows—making ownership conflicts far easier to resolve. Patrina adds a powerful insight: collaboration failures often mirror how leaders talk about (and model) cross-functional partnership.

The conversation gets practical fast. You’ll hear actionable frameworks and behaviors that reduce conflict and build trust, including:

• How to create clarity on “who does what” without diminishing either function
• Why empathy matters—and how simply understanding your partner’s metrics changes everything
• How Medical can avoid being perceived as the “no police” by shifting language from “No” to “How do we get to a shared solution?”
• Why MSLs need stronger “soft skills” training (and why commercial teams often have an advantage here)
• The underrated power of follow-up—and how missing it quietly erodes credibility and internal trust
• How commercial partners can better “position” MSLs with customers by introducing their expertise clearly and confidently

They also touch on the evolving landscape and why changing rules only increases the need for tighter alignment across Medical, Commercial, and Marketing.

If you’ve ever said “that’s my KOL,” felt steamrolled by another function, or struggled to coordinate around the same HCPs—this episode is your playbook. 

If this discussion resonated with you, share it with your organization—and subscribe to scientifica sessions. We deliver unfiltered conversations with the innovators pushing biotech, pharma, and medtech forward.

📧 [email protected]

📧 [email protected]
🔗 LinkedIn: Patrina Pellet, PhD & Chase Wasson

📩 Connect with the show: [email protected]

1. 0:07:06 - Transliminal
2. 00:15:46 - Crystalize
3. 00:35:21 - Panic at the Frisco

Episode recorded on October 14, 2025.  All information shared is current as of the recording date.

Episode Description

In this episode of scientifica sessions, we sit down with Rome Madison—founder of the Genetics for Healthcare podcast and a leading voice in genomic sales enablement and clinician education. With more than two decades of experience helping life-science organizations adopt precision medicine, Rome focuses on translating complex genomic science into practical, real-world clinical action.

He shares how a family health crisis sparked his career at the dawn of the post–Human Genome Project era. We trace the evolution of precision medicine—from early fresh-tissue assays to comprehensive genomic profiling to today’s world of real-world data and AI-supported decision making. Across each phase, one theme remains constant: education—not technology—is the bottleneck to adoption.

We explore why clinicians, payers, and patients still struggle to navigate genomic information, and why medical affairs must serve as the connective tissue between emerging science, commercial priorities, and patient access. Rome also recounts how medical affairs helped challenge restrictive BRCA testing guidelines, expanding access for millions and highlighting what it will take to accelerate similar changes moving forward.

Finally, we look ahead to a healthcare landscape defined by integrated genomic, clinical, wearable, and claims data—one where empowered patients increasingly shape their own care.

The Evolution of Precision Medicine
• From early assays to comprehensive genomic profiling
• How tumor complexity reshaped oncology workflows
• What AI and real-world data add to decision making

Education as the Core Barrier
• Why genomic literacy remains low
• How payer confusion limits testing
• The widening gap between community and academic care

The Role of Medical Affairs (MA)
• How scientific exchange accelerates adoption
• Why MA is essential for explaining clinical utility
• How updated BRCA guidelines expanded equitable access

Industry Enablement Challenges
• Why sales teams struggle with genomic complexity
• The need for aligned scientific and commercial messaging
• How MA + sales partnerships build clinician trust

The Future of Personalized Care
• Integrated genomic, wearable, and EMR data
• AI-driven tools at the point of care
• The rise of informed, empowered patients

If you want to understand what’s holding precision medicine back—and what it will take to finally unlock its full potential—this is a conversation you don’t want to miss.

If this discussion raised new questions about how your teams educate clinicians, enable sales, or expand access to genomic testing, share it with your organization—and subscribe to scientifica sessions. We deliver unfiltered conversations with the innovators pushing biotech, pharma, and medtech forward.

📧 [email protected]
🌐 geneticsforhealthcare.com
🔗 LinkedIn: Rome Madison

📩 Connect with the show: [email protected]

1. 00:10:48 — Micronova
2. 00:19:20 — Slider
3. 00:31:42 — Sepulveda Pass
4. 00:46:25 — Transliminal

Episode recorded July 16, 2025. All information current as of recording.

In this episode of scientifica sessions, we take an unfiltered look at the complex relationship between innovation, privacy, and power in healthcare data with Ardy Arianpour, CEO and Co-Founder of SEQSTER.

The life sciences industry is overflowing with data—EHRs, genomic profiles, claims data, wearables, and AI-driven predictions—but more data doesn't always mean better decisions. Together with host Tabari Baker, Ardy explores what happens when the pursuit of precision meets the realities of fragmentation, bias, and inequity.

They unpack the hidden challenges behind the data revolution: the illusion of completeness in large datasets, the ethical tension between personalization and surveillance, and the growing misalignment between global privacy frameworks and real-world innovation. From AI model bias to the regulatory maze that stifles collaboration, this conversation challenges industry leaders to rethink how data is collected, governed, and used responsibly across research and patient engagement.

Whether you're leading Medical Affairs, building digital health infrastructure, or shaping data strategy in biotech or pharma, this episode offers a grounded perspective on how to move toward a transparent, patient-centric data economy—one that values trust as much as technology.

• Data Abundance, Insight Scarcity
• The Ethics of Data Ownership
• The Regulatory Maze
• Toward a Responsible Data Future

Ardy Arianpour is the CEO and Co-Founder of SEQSTER, the pioneering health-tech company putting patients at the center of their health data. A visionary executive with more than 20 years of experience in life sciences, pharma, and digital health, Ardy has dedicated his career to breaking barriers in how health data is accessed, shared, and used to improve outcomes.

He has been recognized as a PharmaVoice 100 Inspiring Leader (2023 & 2024), a Top 40 Healthcare Transformer, and one of Insights Success' Top 10 Pioneers Redefining Healthcare. Ardy serves as Faculty at NextMed.Health, Judge for the Top Tech Awards, and an Advisor to UCSD's Digital Health Board, Inside Precision Medicine, and the Fleet Science Center.

📧 [email protected]
🌐 seqster.com
🔗 LinkedIn: Ardy Arianpour

If this conversation made you rethink how your organization handles data, governance, and trust, share it with your team—and subscribe to Scientifica Sessions. We bring you unscripted conversations with the people defining the future of biotech, pharma, and medtech.

📩 Connect with the show at [email protected].

At scientifica sessions, we love our music!  Here's are the original tracks used:

1. 00:08:32 - Where Are We Going?

2. 00:15:15 - Bring the Hustle

3. 00:20:45 - Crystalize

4. 00:29:45 - Soyuz Space Guitar

5. 00:39:10 - Lore

Episode recorded on October 22, 2025.  All information shared is current as of the recording date.

In this episode of scientifica sessions, we dive into the rapidly evolving world of real-world evidence (RWE) and patient-generated health data (PGHD) with Drew Schiller, Co-Founder and CEO of Validic. As life sciences companies increasingly look beyond traditional clinical trials, Drew shares how data from wearables, remote monitoring devices, and connected health platforms can be used—even by resource-constrained startups—to support medical strategy, evidence generation, and value-based care.

The conversation explores how early-stage biotechs and emerging life sciences companies can responsibly harness patient-generated data without massive infrastructure investment or regulatory missteps. Drew offers practical guidance on where PGHD fits within the broader evidence ecosystem, how Medical Affairs and clinical teams can use it effectively, and what leaders need to understand as the line between wellness tools and regulated medical devices continues to blur.

Tabari and Drew also discuss the evolving regulatory environment, including the FDA’s recent action related to WHOOP’s Blood Pressure Insights feature, and what it signals for companies integrating wearable and remote monitoring data. The episode highlights how to balance innovation with compliance—and why getting this right is essential for long-term credibility and scalability.

Whether you’re building a lean startup or operating at commercial scale, this episode provides concrete strategies for leveraging real-world data to improve patient outcomes, strengthen value narratives, and support modern, value-based care models.

RWE & PGHD Foundations

• Defining real-world evidence for resource-limited companies
• Where patient-generated data fits in the evidence landscape
• Common misconceptions about collecting and using real-world data

Practical Life Sciences Use Cases

• The most accessible PGHD sources for lean teams
• Using RWE to inform medical and clinical strategy
• Opportunities for personalization and continuous insight generation
• Balancing privacy, interoperability, and evidence quality

PGHD, Pharma Strategy & Value-Based Care

• How patient-generated data supports value-based care models
• The shift from volume to value—and its impact on evidence strategy
• Real-world examples of remote monitoring in action
• Why Medical Affairs and Commercial teams should prioritize PGHD

Regulatory Considerations

• Lessons from the FDA’s WHOOP action
• Navigating the boundary between wellness tools and medical devices
• Staying compliant while leveraging continuous data streams
• The future of life sciences–digital health partnerships

Strategic Guidance for Leaders

• Considerations for CMOs and VPs of Medical Affairs
• The role of PGHD in value dossiers and HEOR submissions
• Platform decisions for startups versus larger organizations

If this conversation sparked new ideas, subscribe to scientifica sessions for unfiltered conversations with the leaders shaping what’s next in biotech, medtech, and pharma.

Contact the show: [email protected]

Original music featured in this episode:
Whirl · A Night in November · Night Walk · Rico Clave · Bubble Trouble · UP! · A Different Cat

Episode recorded July 21, 2025. All information is current as of the recording date.

In this inaugural episode, host Tabari Baker, Founder & CEO of kronos scientifica, introduces Scientifica Sessions—a new podcast at the intersection of science, strategy, and commercialization.

With over 15 years of leadership experience in medical affairs, clinical development, and biotech commercialization, Tabari has worked with companies navigating late-stage trials, preparing for launch, and building medical organizations ready for global growth. He's seen firsthand that great science alone isn't enough—it takes evidence, strategy, and authentic engagement to bring innovation from concept to clinic.

This episode sets the stage for what's to come: candid conversations with scientists, biotech founders, investors, patient advocates, and industry leaders who are shaping the future of medicine. Expect clear insights, practical lessons, and stories that go beyond the headlines.

Whether you're an executive, a founder, or simply curious about how science becomes solutions, this is your invitation to join the conversation.

Subscribe now to hear future episodes of scientifica sessions, and discover what it really takes to turn ideas into impact.

Like what you heard?  Check out our producers, Thread and Tensor.